{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:26:45Z","timestamp":1777530405532,"version":"3.51.4"},"reference-count":83,"publisher":"European Respiratory Society (ERS)","issue":"1","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2018,1,11]]},"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>For another year, high-quality research studies from around the world transformed the annual ERS International Congress into a vivid platform to discuss trending research topics, to produce new research questions and to further push the boundaries of respiratory medicine and science. This article reviews only some of the high-quality research studies on asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and chronic cough that were presented during the congress through the Airway Diseases Assembly (ERS Assembly 5) and places them into the context of current knowledge and research challenges.<\/jats:p>","DOI":"10.1183\/23120541.00163-2017","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:10:23Z","timestamp":1520986223000},"page":"00163-2017","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Research highlights from the 2017 ERS International Congress: airway diseases in focus"],"prefix":"10.1183","volume":"4","author":[{"given":"Cecilia","family":"Andersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara J.","family":"Bonvini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Satia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Idzko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinoud","family":"Gosens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Lopez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Bossios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Spanevello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G.","family":"Mathioudakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"2024101707062990000_4.1.00163-2017.1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S2213-2600(15)00056-9","article-title":"Asthma diagnosis: addressing the challenges","volume":"3","author":"Pavord","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024101707062990000_4.1.00163-2017.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69290-8"},{"key":"2024101707062990000_4.1.00163-2017.3","doi-asserted-by":"publisher","DOI":"10.1159\/000338998"},{"key":"2024101707062990000_4.1.00163-2017.4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.drudis.2016.11.008","article-title":"New concepts in asthma: clinical phenotypes and pathophysiological mechanisms","volume":"22","author":"Koczulla","year":"2017","journal-title":"Drug Discov Today"},{"key":"2024101707062990000_4.1.00163-2017.5","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1513\/AnnalsATS.201304-087AW","article-title":"How variability in clinical phenotypes should guide research into disease mechanisms in asthma","volume":"10","author":"Chung","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"2024101707062990000_4.1.00163-2017.6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1164\/rccm.201604-0866OC","article-title":"A severe asthma disease signature from gene expression profiling of peripheral blood from U-BIOPRED cohorts","volume":"195","author":"Bigler","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101707062990000_4.1.00163-2017.7","first-page":"OA3442","article-title":"Late breaking abstract - comparison of the blood transcriptomic profiles of adults and children from the U-BIOPRED asthma study","volume":"50","author":"Affleck","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.8","doi-asserted-by":"publisher","DOI":"10.1111\/all.12136"},{"key":"2024101707062990000_4.1.00163-2017.9","doi-asserted-by":"crossref","unstructured":"Hekking P-P , Loza MJ , Pavlidis S , et al. Pathway discovery using transcriptomic profiles in adult-onset severe asthma. J Allergy Clin Immunol 2017; in press [https:\/\/doi.org\/10.1016\/j.jaci.2017.06.037].","DOI":"10.1016\/j.jaci.2017.06.037"},{"key":"2024101707062990000_4.1.00163-2017.10","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1944"},{"key":"2024101707062990000_4.1.00163-2017.11","first-page":"OA278","article-title":"Molecular evidence of Group 1 innate lymphoid cell activation in the U-BIOPRED cohort","volume":"50","author":"Pavlidis","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coi.2017.07.017","article-title":"Immune mechanisms of respiratory viral infections in asthma","volume":"48","author":"Farne","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"2024101707062990000_4.1.00163-2017.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6989.1225"},{"key":"2024101707062990000_4.1.00163-2017.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092410"},{"key":"2024101707062990000_4.1.00163-2017.15","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.3.8810601"},{"key":"2024101707062990000_4.1.00163-2017.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2010.08.004"},{"key":"2024101707062990000_4.1.00163-2017.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200406-730OC"},{"key":"2024101707062990000_4.1.00163-2017.18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaci.2017.07.025","article-title":"Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness","volume":"140","author":"Edwards","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024101707062990000_4.1.00163-2017.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-2397"},{"key":"2024101707062990000_4.1.00163-2017.20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaci.2016.03.049","article-title":"Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence","volume":"139","author":"Rubner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024101707062990000_4.1.00163-2017.21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nm.4332","article-title":"Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation","volume":"23","author":"Toussaint","year":"2017","journal-title":"Nature Med"},{"key":"2024101707062990000_4.1.00163-2017.22","first-page":"PA1140","article-title":"Ex vivo virus infection of HDM-sensitized lung tissue proves inadequate anti-viral immune response in small airways","volume":"50","author":"Danov","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.23","first-page":"23","article-title":"Regulation of interleukin 33\/ST2 signaling of human corneal epithelium in allergic diseases","volume":"6","author":"Lin","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"2024101707062990000_4.1.00163-2017.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906312"},{"key":"2024101707062990000_4.1.00163-2017.25","first-page":"PA1138","article-title":"Late breaking abstract - IL-33 drives influenza-induced exacerbations of asthma by halting anti-viral and Th1 responses","volume":"50","author":"Ravanetti","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.26","first-page":"PA4767","article-title":"IL-33 mRNA in induced sputum cells from allergic rhinitis and asthma patients: a marker of Th-2 phenotype status?","volume":"50","author":"Haccuria","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.27","first-page":"PA4917","article-title":"RAGE-dependent VCAM-1 expression in the pulmonary endothelium mediates IL-33 induced asthma pathogenesis","volume":"50","author":"Perkins","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802387"},{"key":"2024101707062990000_4.1.00163-2017.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03867.x"},{"key":"2024101707062990000_4.1.00163-2017.30","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12071"},{"key":"2024101707062990000_4.1.00163-2017.31","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jaci.2016.02.039","article-title":"Aeroallergen-induced IL-33 predisposes to respiratory virus-induced asthma by dampening antiviral immunity","volume":"138","author":"Lynch","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024101707062990000_4.1.00163-2017.32","doi-asserted-by":"crossref","unstructured":"Werder RB , Zhang V , Lynch JP , et al. Chronic IL-33 expression predisposes to viral-induced exacerbations of asthma by increasing type 2 inflammation and dampening antiviral immunity. J Allergy Clin Immunol 2017; in press [https:\/\/doi.org\/10.1016\/j.jaci.2017.07.051].","DOI":"10.1016\/j.jaci.2017.07.051"},{"key":"2024101707062990000_4.1.00163-2017.33","first-page":"PA567","article-title":"IL-33 augments rhinovirus-induced type 2 immune responses in asthma via selective upregulation of one chain of the IL-33 receptor","volume":"50","author":"Upham","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00214-2017"},{"key":"2024101707062990000_4.1.00163-2017.35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101707062990000_4.1.00163-2017.36","first-page":"PA3248","article-title":"Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study","volume":"50","author":"Naya","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.37","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"2024101707062990000_4.1.00163-2017.38","first-page":"PA3949","article-title":"Effect of CHF5993 pMDI (extrafine beclometasone dipropionate: BDP, formoterol fumarate: FF, glycopyrronium bromide: GB) on clinically important deteriorations (CID) in COPD: post-hoc analysis of TRINITY study","volume":"50","author":"Singh","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"key":"2024101707062990000_4.1.00163-2017.40","first-page":"OA2898","article-title":"Late breaking abstract - extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY","volume":"50","author":"Singh","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516385"},{"key":"2024101707062990000_4.1.00163-2017.42","first-page":"PA936","article-title":"Estimating the number of patients\u2019 needed to treat (NNT) with indacaterol\/glycopyrronium to prevent COPD exacerbations: results from the FLAME study","volume":"50","author":"Bjermer","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.43","first-page":"PA3255","article-title":"Indacaterol\/glycopyrronium (IND\/GLY) reduces the risk of clinically important deterioration (CID) versus salmeterol\/fluticasone (SFC): the FLAME study","volume":"50","author":"Anzueto,","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.44","first-page":"PA1075","article-title":"Respiratory safety profile of indacaterol\/glycopyrronium (IND\/GLY) versus salmeterol\/fluticasone (SFC): results from the FLAME study","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.45","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0250-2"},{"key":"2024101707062990000_4.1.00163-2017.46","first-page":"PA679","article-title":"Efficacy of aclidinium\/formoterol: pooled post hoc analysis of patients na\u00efve to COPD maintenance therapy","volume":"50","author":"Singh","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.47","first-page":"PA687","article-title":"ACTIVATE: effect of aclidinium\/formoterol on physical activity in patients with COPD","volume":"50","author":"Watz","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.rmed.2017.08.008","article-title":"GOLD 2017 treatment pathways in \u2018real life\u2019: an analysis of the DACCORD observational study","volume":"131","author":"Worth","year":"2017","journal-title":"Respir Med"},{"key":"2024101707062990000_4.1.00163-2017.49","first-page":"PA1070","article-title":"Low rate of exacerbations following initiation of LABA\/LAMA fixed-dose combinations: an analysis of the DACCORD real life study","volume":"50","author":"Buhl","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.50","first-page":"OA1490","article-title":"The TLR5 agonist flagellin prevents bacteria-induced chronic obstructive pulmonary disease exacerbations in mice","volume":"50","author":"Gosset","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-204"},{"key":"2024101707062990000_4.1.00163-2017.52","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.05.020415"},{"key":"2024101707062990000_4.1.00163-2017.53","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024101707062990000_4.1.00163-2017.54","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"2024101707062990000_4.1.00163-2017.55","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00062614"},{"key":"2024101707062990000_4.1.00163-2017.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402895"},{"key":"2024101707062990000_4.1.00163-2017.57","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1164\/rccm.201612-2427OC","article-title":"Allergen-induced increases in sputum levels of Group 2 innate lymphoid cells in subjects with asthma","volume":"196","author":"Chen","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101707062990000_4.1.00163-2017.58","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"2024101707062990000_4.1.00163-2017.59","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00146306"},{"key":"2024101707062990000_4.1.00163-2017.60","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"2024101707062990000_4.1.00163-2017.61","first-page":"OA1967","article-title":"Late breaking abstract - the prevalence and burden of Pseudomonas aeruginosa among bronchiectasis patients in Europe - data from the FRIENDS cohort","volume":"50","author":"Chalmers","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.62","first-page":"OA1969","article-title":"Sputum pregnancy zone protein (PZP) - a potential biomarker of bronchiectasis severity","volume":"50","author":"Smith","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.63","first-page":"OA466","article-title":"Late breaking abstract - reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline","volume":"50","author":"Froehlich","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.64","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00078-09"},{"key":"2024101707062990000_4.1.00163-2017.65","doi-asserted-by":"crossref","first-page":"28698","DOI":"10.1038\/srep28698","article-title":"Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients","volume":"6","author":"Menzel","year":"2016","journal-title":"Sci Rep"},{"key":"2024101707062990000_4.1.00163-2017.66","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12233"},{"key":"2024101707062990000_4.1.00163-2017.67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1937"},{"key":"2024101707062990000_4.1.00163-2017.68","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2290"},{"key":"2024101707062990000_4.1.00163-2017.69","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70185-1"},{"key":"2024101707062990000_4.1.00163-2017.70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60953-2"},{"key":"2024101707062990000_4.1.00163-2017.71","first-page":"PA4059","article-title":"PROGNOSIS - the German Bronchiectasis Registry: first results","volume":"50","author":"Mertsch","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.72","first-page":"PA4058","article-title":"Phenotype characterization of non-cystic fibrosis bronchiectasis in India","volume":"50","author":"Dhar","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.73","first-page":"1","article-title":"Ambulatory medical care utilization estimates for 2007","volume":"12","author":"Schappert","year":"2011","journal-title":"Vital Heath Statistics"},{"key":"2024101707062990000_4.1.00163-2017.74","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1_suppl.72S"},{"key":"2024101707062990000_4.1.00163-2017.75","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/archinte.158.15.1657","article-title":"Impact of chronic cough on quality of life","volume":"158","author":"French","year":"2010","journal-title":"Arch Intern Med"},{"key":"2024101707062990000_4.1.00163-2017.76","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1378\/chest.14-1485","article-title":"Overview of the management of cough: CHEST guideline and expert panel report","volume":"146","author":"Irwin","year":"2014","journal-title":"Chest"},{"key":"2024101707062990000_4.1.00163-2017.77","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205661"},{"key":"2024101707062990000_4.1.00163-2017.78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61255-1"},{"key":"2024101707062990000_4.1.00163-2017.79","first-page":"OA2932","article-title":"Inhibition of P2X3 by MK-7264 reduces 24-hour cough frequency in a randomized, controlled, Phase 2b clinical trial","volume":"50","author":"Smith","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.80","first-page":"OA2931","article-title":"The Effect of MK-7264, a P2X3 antagonist, on cough reflex sensitivity in a randomized crossover trial of healthy and chronic cough subjects","volume":"50","author":"Morice","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.81","first-page":"OA4410","article-title":"Activation of transient receptor potential (TRP) channels by hypoosmolar solution: an endogenous mechanism of ATP release and afferent nerve activation","volume":"50","author":"Bonvini","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.82","first-page":"OA4409","article-title":"The antitussive effects of alpha7 (\u03b17) nicotinic receptor agonists","volume":"50","author":"Dicpinigatis","year":"2017","journal-title":"Eur Respir J"},{"key":"2024101707062990000_4.1.00163-2017.83","first-page":"OA1491","article-title":"EP2 & EP4 receptor agonists inhibit the airway sensory nerves that cause cough, a potential protective control that is lost in human smokers and a pre-clinical COPD model","volume":"50","author":"Wortley","year":"2017","journal-title":"Eur Respir J"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00163-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:55:34Z","timestamp":1740372934000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00163-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3,13]]},"published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1183\/23120541.00163-2017"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00163-2017","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}